Top Markets
Coin of the day
Myovant Sciences Ltd. Myovant Sciences Ltd.

Myovant Sciences Ltd.

MYOV
Classifica tra le azioni #5525
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating... Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Prezzo delle azioni
$26.98
Ultima sincronizzazione: 2023-03-09
Capitalizzazione di mercato
$2.62B
Variazione (1 giorno)
-0.04%
Variazione (1 anno)
0.00%
Paese
GB
Scambia Myovant Sciences Ltd. (MYOV)

Categoria

Storico del prezzo dell'azione per Myovant Sciences Ltd. (MYOV)
Prezzo di chiusura più alto: $26.97 il 2023-03-01

Prezzo di chiusura più basso: $12.79 il 2016-10-01
Storico del prezzo dell'azione di Myovant Sciences Ltd. dal 2016 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2023 0.28%
2022 73.07%
2021 -37.07%
2020 50.47%
2019 -4.83%
2018 41.15%
2017 8.58%
2016 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$763.69 6.97%
CH